Ahmedabad-based pharmaceutical company Amanta Healthcare Limited is set to launch its initial public offering (IPO) in the first week of September 2025. The company, known for manufacturing sterile liquid products and medical devices, aims to raise fresh capital to expand its production capacity and strengthen its presence in the market.
Lets check out the Amanta Healthcare IPO: Date, Price Band, GMP, Review and Full Details.
IPO Dates and Schedule
- Issue Opens: September 1, 2025
- Issue Closes: September 3, 2025
- Anchor Investor Bidding: August 29, 2025
- Allotment Date: September 4, 2025
- Refunds & Demat Credits: September 5, 2025
- Listing Date: Expected around September 8–9, 2025 on BSE and NSE
Price Band and Lot Size
- Price Band: ₹120 – ₹126 per share
- Lot Size: 119 shares per lot
- Minimum Investment: ₹14,994 (at the lower price band)
Issue Size and Allocation
- Fresh Issue: 1 crore equity shares (approx. ₹120–126 crore)
- QIBs (Qualified Institutional Buyers): Up to 50%
- Retail Investors: At least 35%
- Non-Institutional Investors (NIIs): At least 15%
Grey Market Premium (GMP)
According to market, Amanta Healthcare IPO is trading at a GMP of around ₹18, which represents a premium of around 14% over the upper price band. However, investors should note that GMP is an unofficial indicator and may fluctuate depending on demand and market conditions.
Company Overview
Founded in 1994 and headquartered in Gujarat, Amanta Healthcare specializes in sterile liquid formulations such as:
- IV fluids (large and small volumes)
- Ophthalmic and respiratory products
- Irrigation solutions and eye lubricants
- First-aid and medical consumables
The company uses advanced packaging technologies such as ABFS and ISBM. Its products are supplied through over 320 distributors across India and exported to over 21 countries including Africa, Latin America and Europe.
Financial Performance (FY25)
- Revenue: ₹276.09 crore (slightly down from ₹281.61 crore in FY24)
- Profit After Tax (PAT): ₹10.5 crore (up 189% YoY from ₹3.63 crore)
- EBITDA: ₹59.7 crore with a margin of 21.7%
The company has shown strong improvement in profitability, supported by better operating efficiency.
Use of IPO Proceeds
The raised capital will be used for:
- Setting up a new SteriPort manufacturing line at Hariyala, Kheda (₹70 crore)
- Establishing a new SVP line at the same facility (₹30.13 crore)
- General corporate purposes
Review and Outlook
Amanta Healthcare operates in a high-demand segment of the pharmaceutical industry, with a strong distribution network and global presence. Its recent profit growth further adds to its attractiveness.
In addition, investors should also consider the competitive nature of the pharmaceutical market and regulatory challenges before investing.
Contact Information
Amanta Healthcare Limited
- Address: 8th Floor, Shaligram Corporates, C.J. Marg, Ambli, Ahmedabad, Gujarat – 380058
- Phone: 079-6777-7600
- Email: cs@amanta.co.in
- Website: www.amanta.co.in
Registrar: MUFG Intime India Pvt Ltd
- Phone: +91-22-4918-6270
- Email: amantahealthcare.ipo@linkintime.co.in
- Website: in.mpms.mufg.com/Initial_Offer/public-issues.html
Book Running Lead Manager: Beeline Capital Advisors Pvt Ltd
Leave a Reply